H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Leuk Res. 2013 May;37(5):510-5. doi: 10.1016/j.leukres.2012.12.012. Epub 2013 Jan 16.
Azacitidine's efficacy in therapy-related myeloid neoplasms (t-MN) has not been well-studied. In our retrospective review of 84 t-MN patients treated with azacitidine, median overall survival (OS) was 14.5 months and overall response rate was 43%, including 11% complete remission, 4% marrow complete remission, and 11% partial remission. In patients who underwent allogeneic transplant (25%), median OS was 19.2 versus 12.8 months (P=0.023) for those who did not. Response rates were comparable to those reported for de novo myelodysplastic syndrome. When we analyzed outcomes according to five scoring systems, only the Global MD Anderson Risk Model predicted survival with statistical significance.
阿扎胞苷在治疗相关性髓系肿瘤（t-MN）中的疗效尚未得到充分研究。在对 84 例接受阿扎胞苷治疗的 t-MN 患者的回顾性分析中，中位总生存期（OS）为 14.5 个月，总缓解率为 43%，包括 11%的完全缓解率、4%的骨髓完全缓解率和 11%的部分缓解率。在接受异基因移植的患者（25%）中，中位 OS 为 19.2 个月，而未接受移植的患者为 12.8 个月（P=0.023）。缓解率与新诊断的骨髓增生异常综合征报告的缓解率相当。当我们根据五个评分系统分析结果时，只有全球 MD 安德森风险模型具有统计学意义。
